Drug Trial Radar · NCT07340138
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3
Actual
Start
Apr 15, 2026
Primary completion
Jul 23, 2026
Study completion Sep 21, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
Conditions
- Primary Myelofibrosis (PMF)
- Post-polycythemia Vera Myelofibrosis (Post-PV MF)
- Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
PelabresibDrug
125 mg orally once daily (QD) on Days 1-14 of each 21-day cycle
RuxolitinibDrug
5-25 mg twice daily (BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs)Time frame: Up to 21 days
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Through study completion, an average of approximately 4 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Kamogawa, Chiba, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Chūō, Yamanashi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.